Citadel Advisors
CNTB

Citadel Advisors’s Connect Biopharma Holdings CNTB Stock Holding History

Citadel Advisors’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$199K Sell
76,074
-23,419
-24% -$61K ﹤0.01% 11425
2025
Q4 		$281K Buy
+99,493
New +$212K ﹤0.01% 10281
2025
Q3 		– Sell
-61,992
Closed -$62K – 12908
2025
Q2 		$62K Buy
+61,992
New +$49.4K ﹤0.01% 11662
2022
Q3 		– Sell
-409,659
Closed -$357K – 12726
2022
Q2 		$357K Buy
+409,659
New +$603K ﹤0.01% 9415
2022
Q1 		– Sell
-15,273
Closed -$79K – 13699
2021
Q4 		$79K Sell
15,273
-4,010
-21% -$44.6K ﹤0.01% 12950
2021
Q3 		$461K Sell
19,283
-11,245
-37% -$254K ﹤0.01% 10072
2021
Q2 		$596K Sell
30,528
-214,663
-88% -$3.58M ﹤0.01% 9638
2021
Q1 		$4.54M Buy
+245,191
New +$4.17M ﹤0.01% 4463

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Citadel Advisors's CNTB Position: Q1 2026 in Review

Citadel Advisors reduced its Connect Biopharma Holdings (CNTB) stake by 24% in Q1 2026, selling an estimated $61K and leaving 76,074 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #11425.

Citadel Advisors first reported a position in CNTB in Q1 2021 and has held it in 8 quarters since. The position peaked at $4.54M in Q1 2021. 41 funds tracked by Wall St. Rank hold CNTB as of Q1 2026.

  • Citadel Advisors held 76,074 shares of Connect Biopharma Holdings worth $199K as of Q1 2026.
  • Citadel Advisors sold 23,419 Connect Biopharma Holdings shares in Q1 2026, an estimated $61K.
  • Connect Biopharma Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11425 holding.
  • Citadel Advisors first reported a position in Connect Biopharma Holdings in Q1 2021 and has held it in 8 quarters since.
  • Citadel Advisors's Connect Biopharma Holdings position peaked at $4.54M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.